Ultragenyx Pharmaceutical Q3 Loss Widens

(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE), Monday reported third-quarter loss of $87.3 million or $1.74 per share, compared with last year's loss of $79.2 million or $1.87 per share.

For the third quarter, Ultragenyx reported $11.8 million in total revenues. For Crysvita, Ultragenyx recognized $5.4 million in profit sharing and royalty revenue from its collaboration and license agreement with Kyowa Hakko Kirin. Mepsevii product revenue for the third quarter was $2.1 million, and UX007 named patient revenue was $0.4 million. Ultragenyx recognized $3.6 million in revenue from its research agreement with Bayer.

Analysts polled by Thomson Reuters estimated loss $1.96 per share on revenues of $11.1 million for the quarter.